Sagimet Biosciences Inc. - Series A Common Stock (SGMT)

Sagimet Biosciences (NASDAQ:SGMT) plans to begin a Phase III study of its oral fatty acid synthase, or FASN, inhibitor denifanstat in moderate-to-severe acne within the next several months, following positive results from a China-based Phase III trial conducted by partner Ascletis, company executive

The biopharma company confirmed it's still aiming at the United States' acne-treatment market.

Curious to know what's happening on the US markets one hour before the close of the markets on Thursday? Join us as we explore the top gainers and losers in today's session.

Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics.

Denifanstat showed positive Phase 3 results in acne, meeting all goals with strong safety, as Sagimet pushes ahead with a second FASN inhibitor trial.

The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs.

Madrigal sells an approved MASH treatment that blasted third-quarter sales views out of the water.